Physician profile
Robbin Wagener
NPI 1821078999
$1,946.14
in general payments reported to CMS, 2019-2025
17 companies · $704 in 2025
The $704 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $87.74 · 2021: $160 · 2022: $19.98 · 2023: $368 · 2024: $402 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $297.31 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $267.82 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $243.95 | 2023-2025 | Xiidra, Miebo, Infuse |
| Novartis Pharmaceuticals Corporation | $186.58 | 2020-2023 | |
| Alcon Vision LLC | $186.04 | 2023-2025 | Rocklatan, Eysuvis, Tryptyr |
| Oyster Point Pharma, INC. | $170.19 | 2023-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $148.64 | 2019 | |
| Abbvie INC. | $88.58 | 2024-2025 | |
| Alimera Sciences, INC. | $86.01 | 2020-2021 | |
| Harrow Eye, LLC | $73.58 | 2024-2025 | Vevye |
| Amgen INC. | $40.71 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $39.56 | 2021-2022 | |
| Coopervision INC. | $33.44 | 2023-2025 | Clariti Contact Lens, Myday Contact Lens |
| Biotissue Holdings INC. | $24.53 | 2023 | |
| Aerie Pharmaceuticals, INC. | $23.90 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.03 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbin Wagener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.